Rankings / Cognitive
Cognitive — Prescription Stimulants
Adderall, Vyvanse, modafinil, solriamfetol. Strong evidence in ADHD and narcolepsy, small effects in healthy users, real cardiovascular and dependency risk.
| # | Compound | Ev | Bn | Sf | Grade · Score |
|---|---|---|---|---|---|
| 1 | Centanafadine NDRI / triple reuptake inhibitor (non-stimulant ADHD) | 8 | 5 | 7 | B+ 7.2 |
| 2 | Viloxazine (Qelbree) Non-stimulant ADHD / norepinephrine-serotonin modulator | 8 | 5 | 7 | B+ 7.2 |
| 3 | Bromantane (Ladasten) Russian psychostimulant / actoprotector | 4.5 | 5 | 9 | B 6.4 |
| 4 | Vyvanse (lisdexamfetamine) Prescription stimulant | 8 | 6.5 | 3.5 | B- High-risk profile 6 |
| 5 | Mazindol ER (Quilience) Wakefulness / non-amphetamine stimulant (narcolepsy, ADHD) | 6 | 5 | 5 | C+ 5.5 |
| 6 | Adderall (amphetamine salts) Prescription stimulant | 8 | 6.5 | 2 | C+ High-risk profile 5.4 |
| 7 | Ephedrine / pseudoephedrine / synephrine stimulants Sympathomimetic stimulant | 6 | 5 | 3.5 | C High-risk profile 4.9 |
| 8 | Methylphenidate / phenidate stimulants Prescription stimulant / dopamine-norepinephrine reuptake inhibitor | 6 | 5 | 3.5 | C High-risk profile 4.9 |
These are the prescription wakefulness and ADHD drugs — Adderall, Vyvanse, modafinil, solriamfetol and relatives. They have strong, well-established efficacy for their approved indications, and a much smaller and riskier story as off-label "study drugs" for healthy users. The rankings score both the evidence and the safety cost, which is genuine.
Where the evidence is strong
Amphetamines (Adderall, Vyvanse) and methylphenidate are highly effective in diagnosed ADHD — among the larger effect sizes in psychiatry. Modafinil and armodafinil are well evidenced for narcolepsy and shift-work disorder; solriamfetol and pitolisant address excessive daytime sleepiness. Matched to the right diagnosis, these drugs work and work well.
The healthy-user reality
In people without ADHD, the cognitive benefit is smaller and less consistent than the reputation implies. Modafinil’s effects on rested, healthy users are modest, and amphetamines tend to raise confidence and wakefulness more than actual problem-solving. The trade is real risk: cardiovascular strain, sleep disruption, and dependency, escalating from the wakefulness agents to the Schedule II stimulants.
Scheduling and risk
Most of these are controlled: modafinil and solriamfetol are Schedule IV, while amphetamines are Schedule II. Pitolisant is a non-scheduled exception. Approved indications, off-label healthy-user evidence, legal status, and safety findings are shown as separate contexts.
Frequently asked
Does modafinil make you smarter?
Not exactly. It promotes wakefulness and clearly helps in sleep-deprived states and narcolepsy, but in rested, healthy users its cognitive effects are modest and inconsistent. It is a Schedule IV prescription drug, not a clean nootropic.
How do the evidence profiles for Adderall, Vyvanse, and modafinil differ?
The studied purposes differ. Amphetamines such as Adderall and Vyvanse have large effects in diagnosed ADHD alongside higher dependency and cardiovascular risk and Schedule II status. Modafinil has stronger evidence for wakefulness disorders, a different adverse-effect profile, and Schedule IV status. All are prescription drugs.
What risks are reported with occasional healthy-user stimulant use?
Reported risks include cardiovascular strain, sleep disruption, and dependency potential, with higher concern for amphetamine-class stimulants. Evidence for occasional healthy-user use is thinner than evidence in diagnosed ADHD or wakefulness disorders, and the compounds retain prescription and controlled status.
Scores reflect the published evidence, not a recommendation to use any compound or protocol. Nothing here is medical advice. How we score →